Global Blood Therapeutics, Inc. (GBT)
(Delayed Data from NSDQ)
$55.18 USD
+1.34 (2.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $55.12 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.18 USD
+1.34 (2.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $55.12 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Global Blood (GBT) delivered earnings and revenue surprises of 2.33% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Global Blood Therapeutics (GBT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Global Blood (GBT) Up 15.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/Y
by Zacks Equity Research
Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly above estimates.
Global Blood Therapeutics (GBT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Global Blood (GBT) delivered earnings and revenue surprises of -19.30% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More
by Zacks Equity Research
Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Global Blood (GBT) Gets FDA Nod for Oxbryta Label Expansion
by Zacks Equity Research
The FDA approves Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to less the 12 years, and NDA for a pediatric weight-based formulation of the drug.
Forma's (FMTX) Etavopivat Proves Safety Profile in SCD Study
by Zacks Equity Research
Forma's (FMTX) investigational PKR activator, etavopivat significantly improves anemia and red blood cell health in patients with sickle cell disease.
Global Blood's (GBT) Earnings & Revenues Lag Estimates in Q3
by Zacks Equity Research
Global Blood (GBT) reports wider-than-expected loss in the third quarter of 2021 while its revenues miss estimates.
Global Blood Therapeutics (GBT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Global Blood (GBT) delivered earnings and revenue surprises of -2.73% and -3.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Global Blood Therapeutics (GBT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Global Blood's (GBT) NDA & sNDA for Oxbryta Get Priority Review
by Zacks Equity Research
The FDA grants priority review to Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to 11 years, as well as to its NDA for a pediatric weight-based formulation of the drug.
Why Is Global Blood (GBT) Down 7.5% Since Last Earnings Report?
by Zacks Equity Research
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe
by Zacks Equity Research
Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The drug has seen solid uptake since its launch. However, sole dependence on Oxbryta for growth remains a concern.
Global Blood's (GBT) Q2 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Global Blood (GBT) reports a narrower-than-expected loss in the second quarter of 2021 while its revenues also beat estimates.
Global Blood Therapeutics (GBT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Global Blood (GBT) delivered earnings and revenue surprises of 4.27% and 8.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Global Blood (GBT) Up 0.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Global Blood's (GBT) Q1 Earnings Miss, Revenues Rise Y/Y
by Zacks Equity Research
Global Blood (GBT) reports a wider-than-expected loss in the first quarter of 2021 and its revenues also miss estimates.
Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Global Blood (GBT) delivered earnings and revenue surprises of -18.63% and -8.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Global Blood Therapeutics (GBT) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Global Blood (GBT) Down 7.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Global Blood (GBT) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Global Blood (GBT) reports a wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates.